IMAX Toekomstige groei

Future criteriumcontroles 3/6

IMAX zal naar verwachting groeien in winst en omzet met respectievelijk 20.9% en 8.6% per jaar. De winst per aandeel zal naar verwachting groeien met 29.2% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 16.8% zijn.

Belangrijke informatie

20.9%

Groei van de winst

29.2%

Groei van de winst per aandeel

Entertainment winstgroei	27.7%
Inkomstengroei	8.6%
Toekomstig rendement op eigen vermogen	16.8%
Dekking van analisten	Good
Laatst bijgewerkt	12 Nov 2024

Recente toekomstige groei-updates

IMAX Corporation Just Recorded A 12% EPS Beat: Here's What Analysts Are Forecasting Next

Mar 01

Recent updates

After Leaping 26% IMAX Corporation (NYSE:IMAX) Shares Are Not Flying Under The Radar

Nov 07

Here's Why IMAX (NYSE:IMAX) Can Manage Its Debt Responsibly

Oct 31

If EPS Growth Is Important To You, IMAX (NYSE:IMAX) Presents An Opportunity

Oct 13

IMAX Corporation: Undervalued Relative To Revenue Growth And Margin Expansion Potential

Oct 10

IMAX Corporation Just Recorded A 12% EPS Beat: Here's What Analysts Are Forecasting Next

Mar 01

When Should You Buy IMAX Corporation (NYSE:IMAX)?

Feb 15

IMAX Corporation: Bull Case Has Merits, But I Am Not Interested

Jan 22

IMAX Corporation: International Expansion Remains A Bright Spot

Nov 19

Some Investors May Be Worried About IMAX's (NYSE:IMAX) Returns On Capital

Oct 13

IMAX Appears Expensive After Post-Pandemic Appreciation

Oct 09

IMAX Corporation Stock: Bullish Following A Blockbuster Summer

Aug 24

Should You Think About Buying IMAX Corporation (NYSE:IMAX) Now?

Jul 31

These Return Metrics Don't Make IMAX (NYSE:IMAX) Look Too Strong

Jul 14

IMAX Corporation: Coming Back To Life

Jun 15

Are Investors Undervaluing IMAX Corporation (NYSE:IMAX) By 31%?

Jun 07

Is It Time To Consider Buying IMAX Corporation (NYSE:IMAX)?

Apr 03

IMAX (NYSE:IMAX) Is Carrying A Fair Bit Of Debt

Mar 13

IMAX Non-GAAP EPS of $0.19 misses by $0.03, revenue of $98M beats by $1.77M

Feb 22

IMAX, Cinema XXI expand relationship with deal for ten new theatres in Indonesia

Feb 14

IMAX (NYSE:IMAX) Has Some Difficulty Using Its Capital Effectively

Feb 06

IMAX Corporation: All Eyes On China

Jan 30

IMAX plans to add seven new locations in Japanese expansion

Jan 19

IMAX China gets new key person

Dec 12

Is IMAX (NYSE:IMAX) A Risky Investment?

Nov 28

IMAX, AMC partner on six new Saudi Arabia theaters

Oct 27

Capital Allocation Trends At IMAX (NYSE:IMAX) Aren't Ideal

Oct 17

IMAX Corporation: Watch Recent Buyback Program Expansion And Acquisition

Oct 04

IMAX acquires streaming technology firm SSIMWAVE in cash-and-stock deal

Sep 22

IMAX doubles buyback plan to $400M

Sep 07

Cineworld, IMAX enter expanded deal for upgraded and new locations

Aug 03

Is IMAX (NYSE:IMAX) Using Too Much Debt?

Jul 28

IMAX Is Recovering, Not Growing

Jul 21

IMAX extends current share repurchase program

Jun 30

IMAX (NYSE:IMAX) Will Be Looking To Turn Around Its Returns

Jun 27

IMAX Corporation: Multiple Tailwinds

Jun 21

Does IMAX (NYSE:IMAX) Have A Healthy Balance Sheet?

Mar 29

IMAX (NYSE:IMAX) Is Finding It Tricky To Allocate Its Capital

Mar 03

IMAX: Determining The Future Of 'Bigger Is Better'

Feb 21

Winst- en omzetgroeiprognoses

NYSE:IMAX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	435	51	100	132	8
12/31/2025	416	51	89	116	11
12/31/2024	379	40	47	81	11
9/30/2024	346	23	19	63	N/A
6/30/2024	358	21	17	57	N/A
3/31/2024	367	26	-9	26	N/A
12/31/2023	375	25	26	59	N/A
9/30/2023	387	25	43	71	N/A
6/30/2023	352	4	21	48	N/A
3/31/2023	328	-7	11	42	N/A
12/31/2022	301	-23	-15	17	N/A
9/30/2022	311	-15	-4	26	N/A
6/30/2022	299	-15	-7	18	N/A
3/31/2022	276	-21	-7	13	N/A
12/31/2021	255	-22	-12	6	N/A
9/30/2021	202	-54	-25	-12	N/A
6/30/2021	183	-93	-29	-19	N/A
3/31/2021	141	-109	-50	-40	N/A
12/31/2020	137	-144	-32	-23	N/A
9/30/2020	205	-104	-28	-8	N/A
6/30/2020	254	-48	-8	21	N/A
3/31/2020	350	-11	56	97	N/A
12/31/2019	396	47	40	90	N/A
9/30/2019	380	30	47	109	N/A
6/30/2019	376	26	46	112	N/A
3/31/2019	370	23	36	94	N/A
12/31/2018	374	23	53	110	N/A
9/30/2018	391	26	41	90	N/A
6/30/2018	408	20	N/A	95	N/A
3/31/2018	397	11	N/A	101	N/A
12/31/2017	381	2	N/A	85	N/A
9/30/2017	362	6	N/A	96	N/A
6/30/2017	349	10	N/A	79	N/A
3/31/2017	353	18	N/A	72	N/A
12/31/2016	376	29	N/A	78	N/A
9/30/2016	389	42	N/A	87	N/A
6/30/2016	388	48	N/A	102	N/A
3/31/2016	404	66	N/A	83	N/A
12/31/2015	374	55	N/A	84	N/A
9/30/2015	357	53	N/A	57	N/A
6/30/2015	332	50	N/A	70	N/A
3/31/2015	305	39	N/A	79	N/A
12/31/2014	291	39	N/A	87	N/A
9/30/2014	293	46	N/A	94	N/A
6/30/2014	284	43	N/A	82	N/A
3/31/2014	286	42	N/A	70	N/A
12/31/2013	288	44	N/A	55	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei IMAX ( 20.9% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van IMAX ( 20.9% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.3% per jaar).

Hoge groeiwinsten: De winst van IMAX zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van IMAX ( 8.6% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.9% per jaar).

Hoge groei-inkomsten: De omzet van IMAX ( 8.6% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen IMAX zal naar verwachting over 3 jaar laag zijn ( 16.8 %).

IMAX Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates increase by 22%, revenue downgraded

Consensus EPS estimates increase by 20%

Price target increased by 8.0% to US$24.36

Consensus EPS estimates increase by 13%

IMAX Corporation Just Recorded A 12% EPS Beat: Here's What Analysts Are Forecasting Next

IMAX Corporation Provides Revenue Guidance for the Fiscal Year 2025

Recent updates

After Leaping 26% IMAX Corporation (NYSE:IMAX) Shares Are Not Flying Under The Radar

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 22%, revenue downgraded

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Here's Why IMAX (NYSE:IMAX) Can Manage Its Debt Responsibly

IMAX Corporation to Report Q3, 2024 Results on Oct 30, 2024

If EPS Growth Is Important To You, IMAX (NYSE:IMAX) Presents An Opportunity

IMAX Corporation Names Jonathan Fischer as Chief Content Officer

IMAX Corporation: Undervalued Relative To Revenue Growth And Margin Expansion Potential

When Should You Buy IMAX Corporation (NYSE:IMAX)?

Returns On Capital At IMAX (NYSE:IMAX) Paint A Concerning Picture

Consensus EPS estimates increase by 20%

IMAX Corporation: Upbeat Mid-Term Outlook After Great Q2 Signings

Price target increased by 8.0% to US$24.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pinning Down IMAX Corporation's (NYSE:IMAX) P/S Is Difficult Right Now

IMAX Corporation to Report Q2, 2024 Results on Jul 25, 2024

Is IMAX (NYSE:IMAX) A Risky Investment?

Is It Too Late To Consider Buying IMAX Corporation (NYSE:IMAX)?

Consensus EPS estimates increase by 13%

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

IMAX Corporation to Report Q1, 2024 Results on Apr 25, 2024

IMAX Corporation: Good Reasons To Be Bullish

Chief Legal Officer & Senior EVP recently sold US$422k worth of stock

IMAX Corporation, Annual General Meeting, Jun 06, 2024

President of IMAX Theatres exercised options and sold US$357k worth of stock

IMAX Corporation Just Recorded A 12% EPS Beat: Here's What Analysts Are Forecasting Next

IMAX Corporation Provides Revenue Guidance for the Fiscal Year 2025

Full year 2023 earnings: EPS exceeds analyst expectations

When Should You Buy IMAX Corporation (NYSE:IMAX)?

IMAX Corporation to Report Q4, 2023 Results on Feb 27, 2024

IMAX Corporation: Bull Case Has Merits, But I Am Not Interested

IMAX Corporation Appoints Anne Globe as Chief Marketing Officer

CEO & Director exercised options and sold US$1.4m worth of stock

IMAX Corporation: International Expansion Remains A Bright Spot

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Some Investors May Be Worried About IMAX's (NYSE:IMAX) Returns On Capital

IMAX Corporation to Report Q3, 2023 Results on Oct 25, 2023

IMAX Appears Expensive After Post-Pandemic Appreciation

IMAX Corporation Stock: Bullish Following A Blockbuster Summer

Should You Think About Buying IMAX Corporation (NYSE:IMAX) Now?

These Return Metrics Don't Make IMAX (NYSE:IMAX) Look Too Strong

IMAX Corporation: Coming Back To Life

Are Investors Undervaluing IMAX Corporation (NYSE:IMAX) By 31%?

CEO & Director recently sold US$2.1m worth of stock

Price target increased by 7.1% to US$23.36

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Is It Time To Consider Buying IMAX Corporation (NYSE:IMAX)?

IMAX (NYSE:IMAX) Is Carrying A Fair Bit Of Debt

President of IMAX Theatres recently sold US$367k worth of stock

Price target increased by 7.4% to US$21.09

Full year 2022 earnings released: US$0.40 loss per share (vs US$0.38 loss in FY 2021)

Price target increased by 7.0% to US$20.82

IMAX Non-GAAP EPS of $0.19 misses by $0.03, revenue of $98M beats by $1.77M

IMAX, Cinema XXI expand relationship with deal for ten new theatres in Indonesia

IMAX Corporation to Report Q4, 2022 Results on Feb 22, 2023

IMAX (NYSE:IMAX) Has Some Difficulty Using Its Capital Effectively

IMAX Corporation: All Eyes On China

IMAX plans to add seven new locations in Japanese expansion

CEO & Director exercised options and sold US$1.3m worth of stock

IMAX Corporation Names Daniel Manwaring as Chief Executive Officer

IMAX China gets new key person

IMAX Corporation Announces Executive Changes

President of IMAX Theatres exercised options and sold US$126k worth of stock

Insider recently sold US$104k worth of stock

Is IMAX (NYSE:IMAX) A Risky Investment?

Price target decreased to US$18.73

Insufficient new directors

Price target decreased to US$19.18